Integrin α5 regulates motility of human monocyte-derived Langerhans cells during immune response.

Langerhans cells cell adhesion cell motility inflammation integrins live cell imaging

Journal

Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549

Informations de publication

Date de publication:
Mar 2024
Historique:
revised: 28 12 2023
received: 22 09 2023
accepted: 12 01 2024
medline: 2 3 2024
pubmed: 2 3 2024
entrez: 1 3 2024
Statut: ppublish

Résumé

Langerhans cells (LCs) are mainly present in the epidermis and mucosa, and have important roles during skin infection. Migration of LCs to lymph nodes is essential for antigen presentation. However, due to the difficulties in isolating and culturing human LCs, it is not fully understood how LCs move and interact with the extracellular matrix (ECM) through their adhesion molecules such as integrin, during the immune responses. In this study, we aimed to investigate LC motility, cell shape and the role of integrin under inflammatory conditions using monocyte-derived Langerhans cells (moLCs) as a model. As a result, lipopolysaccharide (LPS) stimulation increased adhesion on fibronectin coated substrate and integrin α5 expression in moLCs. Time-lapse imaging of moLCs revealed that stimulation with LPS elongated cell shape, whilst decreasing their motility. Additionally, this decrease in motility was not observed when pre-treated with a neutralising antibody targeting integrin α5. Together, our data suggested that activation of LCs decreases their motility by promoting integrin α5 expression to enhance their affinity to the fibronectin, which may contribute to their migration during inflammation.

Identifiants

pubmed: 38429832
doi: 10.1111/exd.15021
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15021

Subventions

Organisme : AMED
ID : 223fa727001
Organisme : AMED
ID : JP223fa727002
Organisme : AMED
ID : JP223fa627001
Organisme : JST CREST
ID : JPMJCR18H1
Organisme : JSPS KAKENHI
ID : JP22K08381

Informations de copyright

© 2024 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.

Références

Deckers J, Hammad H, Hoste E. Langerhans cells: sensing the environment in health and disease. Front Immunol. 2018;9:93.
Yoshida K, Kubo A, Fujita H, et al. Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):856-864.
Cumberbatch M, Singh M, Dearman RJ, Young HS, Kimber I, Griffiths CEM. Impaired Langerhans cell migration in psoriasis. J Exp Med. 2006;203(4):953-960.
Tozluoǧlu M, Tournier AL, Jenkins RP, et al. Matrix geometry determines optimal cancer cell migration strategy and modulates response to interventions. Nat Cell Biol. 2013;15(7):751-762.
Wang Z, Li R, Zhong R. Extracellular matrix promotes proliferation, migration and adhesion of airway smooth muscle cells in a rat model of chronic obstructive pulmonary disease via upregulation of the PI3K/AKT signaling pathway. Mol Med Rep. 2018;18(3):3143-3152.
Lämmermann T, Germain RN. The multiple faces of leukocyte interstitial migration. Semin Immunopathol. 2014;36(2):227-251.
Staquet MJ, Jacquet C, Dezutter-Dambuyant C, Schmitt D. Fibronectin upregulates in vitro generation of dendritic Langerhans cells from human cord blood CD34+ progenitors. J Invest Dermatol. 1997;109(6):738-743.
García-Nieto S, Johal RK, Shakesheff KM, et al. Laminin and fibronectin treatment leads to generation of dendritic cells with superior endocytic capacity. PLoS One. 2010;5(4):e10123.
Price AA, Cumberbatch M, Kimber I, Ager A. Alpha 6 integrins are required for Langerhans cell migration from the epidermis. J Exp Med. 1997;186(10):1725-1735.
Aiba S, Nakagawa S, Ozawa H, et al. Up-regulation of alpha 4 integrin on activated Langerhans cells: analysis of adhesion molecules on Langerhans cells relating to their migration from skin to draining lymph nodes. J Invest Dermatol. 1993;100(2):143-147.
Hamakawa M, Sugihara A, Okamoto H, Horio T. Ultraviolet B radiation suppresses Langerhans cell migration in the dermis by down-regulation of α4 integrin. Photodermatol Photoimmunol Photomed. 2006;22(3):116-123.
Atsumi Y, Toriyama M, Kato H, et al. Anti-inflammatory role of TRPV4 in human macrophages. Immunohorizons. 2023;7(1):81-96.
Otsuka Y, Watanabe E, Shinya E, et al. Differentiation of Langerhans cells from monocytes and their specific function in inducing IL-22-specific Th cells. J Immunol. 2018;201(10):3006-3016.
Park S, Matte-Martone C, Gonzalez DG, et al. Skin-resident immune cells actively coordinate their distribution with epidermal cells during homeostasis. Nat Cell Biol. 2021;23(5):476-484.
Singh TP, Zhang HH, Borek I, et al. Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation. Nat Commun. 2016;7:1-18.
Xiao C, Zhu Z, Sun S, et al. Activation of Langerhans cells promotes the inflammation in imiquimod-induced psoriasis-like dermatitis. J Dermatol Sci. 2017;85(3):170-177.
Villablanca EJ, Mora JR. A two-step model for LC migration to skin draining LNs. Eur J Immunol. 2011;38(11):2975-2980.
Fujiwara H, Gu J, Sekiguchi K. Rac regulates integrin-mediated endothelial cell adhesion and migration on laminin-8. Exp Cell Res. 2004;292(1):67-77.
Neagu M, Constantin C, Jugulete G, et al. Langerhans cells-revising their role in skin pathologies. J Pers Med. 2022;12(12):2072.
Graf BW, Chaney EJ, Marjanovic M, et al. Long-term time-lapse multimodal intravital imaging of regeneration and bone-marrow-derived cell dynamics in skin. Technology. 2013;1(1):8-19.
Nishibu A, Ward BR, Jester JV, Ploegh HL, Boes M, Takashima A. Behavioral responses of epidermal Langerhans cells in situ to local pathological stimuli. J Invest Dermatol. 2006;126(4):787-796.
Gaiser MR, Lämmermann T, Feng X, et al. Cancer-associated epithelial cell adhesion molecule (EpCAM; CD326) enables epidermal Langerhans cell motility and migration in vivo. Proc Natl Acad Sci U S A. 2012;109(15):E889-E897.
Kosten IJ, Spiekstra SW, de Gruijl TD, Gibbs S. MUTZ-3 derived Langerhans cells in human skin equivalents show differential migration and phenotypic plasticity after allergen or irritant exposure. Toxicol Appl Pharmacol. 2015;287(1):35-42.
Loh JT, Su IH. Post-translational modification-regulated leukocyte adhesion and migration. Oncotarget. 2016;7(24):37347-37360.
Lämmermann T, Bader BL, Monkley SJ, et al. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature. 2008;453(7191):51-55.
Ross EC, ten Hoeve AL, Barragan A. Integrin-dependent migratory switches regulate the translocation of toxoplasma-infected dendritic cells across brain endothelial monolayers. Cell Mol Life Sci. 2021;78(12):5197-5212.
Hamouda AEI, Schalla C, Sechi A, Zenke M, Schneider RK, Hieronymus T. Met-signaling controls dendritic cell migration in skin by regulating podosome formation and function. J Invest Dermatol. 2023;143(8):1548-1558.e13.
Wang Y, Jin G, Miao H, Li JYS, Usami S, Chien S. Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras. Proc Natl Acad Sci U S A. 2006;103(6):1774-1779.
Yano H, Mazaki Y, Kurokawa K, Hanks SK, Matsuda M, Sabe H. Roles played by a subset of integrin signaling molecules in cadherin-based cell-cell adhesion. J Cell Biol. 2004;166(2):283-295.
Fei D, Meng X, Yu W, et al. Fibronectin (FN) cooperated with TLR2/TLR4 receptor to promote innate immune responses of macrophages via binding to integrin β1. Virulence. 2018;9(1):1588-1600.
Monick MM, Powers L, Butler N, Yarovinsky T, Hunninghake GW. Interaction of matrix with integrin receptors is required for optimal LPS-induced MAP kinase activation. Am J Physiol Lung Cell Mol Physiol. 2002;283:390-402.

Auteurs

Zhihan Guo (Z)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.

Masato Murakami (M)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Skin Care Institute, Mandom Corporation, Osaka, Japan.

Kaori Saito (K)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Advanced Technology Institute, Mandom Corporation, Osaka, Japan.
Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.

Hiroko Kato (H)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.

Manami Toriyama (M)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara, Japan.

Makoto Tominaga (M)

Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences, Okazaki, Japan.
National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki, Japan.
Department of Physiological Sciences, Sokendai (The Graduate University for Advanced Studies), Okazaki, Japan.

Ken J Ishii (KJ)

Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Division of Vaccine Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Fumitaka Fujita (F)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Advanced Technology Institute, Mandom Corporation, Osaka, Japan.
Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.

Classifications MeSH